Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029

Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029

The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.

Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK’s MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.

“Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market”

Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.

“Hospitals to witness the high growth in the AMD drugs market by End User”

Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.

“Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type”

Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.

“North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market”

The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side -70% and Demand Side – 30%

By Designation: Managers -45%, CXOs and Directors -30%, and Executives – 25%

By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%

Lists of Companies Profiled in the Report:

Regeneron Pharmaceuticals Inc. (US)

Bayer AG (Germany)

F. Hoffmann-La Roche Ltd (Switzerland)

Novartis AG (Switzerland)

Apellis Pharmaceuticals (US)

Coherus BioSciences (US)

Astellas Pharma Inc. (Japan)

Biogen (US)

STADA Arzneimittel AG (Germany)

Formycon AG (Germany)

Biocon. (India)

Outlook Therapeutics, Inc. (US)

Intas Pharmaceuticals Ltd. (India)

Teva Pharmaceutical Industries Ltd. (Israel)

Chengdu Kanghong Biotech Company (China)

Sandoz Group AG (Switzerland)

Stealth BioTherapeutics Inc. (US)

Ocular Therapeutix, Inc. (US)

Opthea Limited (Australia)

Kodiak Sciences Inc. (US)

Innovent Biologics, Inc. (China)

Bio-Thera Solution (China)

Alvotech (Iceland)

Alteogen Inc. (South Korea)

Shanghai Henlius Biotech, Inc. (China)

Amgen Inc. (US)

Ocumension Therapeutics. (China)

Adverum Biotechnologies, Inc. (US)

Research Coverage:

This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.

Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.

Tables List

Table 1 Inclusions And Exclusions

Table 2 Age-related Macular Degeneration (Amd) Drugs Market:

Impact Analysis Of Market Dynamics

Table 3 Average Selling Price Of Age-related Macular Degeneration (Amd) Drugs, By Product (Per Dose), 2021–2023 (Usd)

Table 4 Average Selling Price Of Age-related Macular Degeneration (Amd) Drugs, By Key Player, 2021–2023 (Usd)

Table 5 Age-related Macular Degeneration (Amd) Drugs Market: Role Of Companies In Ecosystem

Table 6 Patents Filed, By Document Type, 2014–2024

Table 7 Innovations And Patent Registrations, 2019–2023

Table 8 North America: Regulatory Bodies, Government Agencies,

And Other Organizations

Table 9 Europe: Regulatory Bodies, Government Agencies,

And Other Organizations

Table 10 Asia Pacific: Regulatory Bodies, Government Agencies,

And Other Organizations

Table 11 Latin America: Regulatory Bodies, Government Agencies,

And Other Organizations

Table 12 Middle East & Africa: Regulatory Bodies, Government Agencies,

And Other Organizations

Table 13 Age-related Macular Degeneration (Amd) Drugs Market:

Porter’s Five Forces Analysis

Table 14 Age-related Macular Degeneration (Amd) Drugs Market:

Key Conferences And Events, 2024–2025

Table 15 Buying Criteria For Age-related Macular Degeneration (Amd) Drugs,

By End User

Table 16 Age-related Macular Degeneration (Amd) Drugs In

Clinical Pipeline, Phase 3

Table 17 Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 18 Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2023–2029 (Million Units)

Table 19 Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Region, 2022–2029 (Usd Million)

Table 20 North America: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Country, 2022–2029 (Usd Million)

Table 21 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Country, 2022–2029 (Usd Million)

Table 22 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Country, 2022–2029 (Usd Million)

Table 23 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Country, 2022–2029 (Usd Million)

Table 24 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Region, 2022–2029 (Usd Million)

Table 25 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Eylea & Eylea Hd, By Country, 2022–2029 (Usd Million)

Table 26 Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Region, 2022–2029 (Usd Million)

Table 27 North America: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Country, 2022–2029 (Usd Million)

Table 28 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Country, 2022–2029 (Usd Million)

Table 29 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Country, 2022–2029 (Usd Million)

Table 30 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Country, 2022–2029 (Usd Million)

Table 31 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Region, 2022–2029 (Usd Million)

Table 32 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Lucentis, By Country, 2022–2029 (Usd Million)

Table 33 Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Region, 2022–2029 (Usd Million)

Table 34 North America: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Country, 2022–2029 (Usd Million)

Table 35 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Country, 2022–2029 (Usd Million)

Table 36 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Country, 2022–2029 (Usd Million)

Table 37 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Country, 2022–2029 (Usd Million)

Table 38 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Region, 2022–2029 (Usd Million)

Table 39 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Vabysmo, By Country, 2022–2029 (Usd Million)

Table 40 Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Region, 2022–2029 (Usd Million)

Table 41 North America: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Country, 2022–2029 (Usd Million)

Table 42 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Country, 2022–2029 (Usd Million)

Table 43 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Country, 2022–2029 (Usd Million)

Table 44 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Country, 2022–2029 (Usd Million)

Table 45 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Region, 2022–2029 (Usd Million)

Table 46 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Syfovre, By Country, 2022–2029 (Usd Million)

Table 47 Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Region, 2022–2029 (Usd Million)

Table 48 North America: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Country, 2022–2029 (Usd Million)

Table 49 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Country, 2022–2029 (Usd Million)

Table 50 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Country, 2022–2029 (Usd Million)

Table 51 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Country, 2022–2029 (Usd Million)

Table 52 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Region, 2022–2029 (Usd Million)

Table 53 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Other Products, By Country, 2022–2029 (Usd Million)

Table 54 Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 55 Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Region, 2022–2029 (Usd Million)

Table 56 North America: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Country, 2022–2029 (Usd Million)

Table 57 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Country, 2022–2029 (Usd Million)

Table 58 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Country, 2022–2029 (Usd Million)

Table 59 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Country, 2022–2029 (Usd Million)

Table 60 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Region, 2022–2029 (Usd Million)

Table 61 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Aflibercept, By Country, 2022–2029 (Usd Million)

Table 62 Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Region, 2022–2029 (Usd Million)

Table 63 North America: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Country, 2022–2029 (Usd Million)

Table 64 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Country, 2022–2029 (Usd Million)

Table 65 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Country, 2022–2029 (Usd Million)

Table 66 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Country, 2022–2029 (Usd Million)

Table 67 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Region, 2022–2029 (Usd Million)

Table 68 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Faricimab, By Country, 2022–2029 (Usd Million)

Table 69 Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Region, 2022–2029 (Usd Million)

Table 70 North America: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Country, 2022–2029 (Usd Million)

Table 71 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Country, 2022–2029 (Usd Million)

Table 72 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Country, 2022–2029 (Usd Million)

Table 73 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Country, 2022–2029 (Usd Million)

Table 74 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Region, 2022–2029 (Usd Million)

Table 75 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Ranibizumab, By Country, 2022–2029 (Usd Million)

Table 76 Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Region, 2022–2029 (Usd Million)

Table 77 North America: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Country, 2022–2029 (Usd Million)

Table 78 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Country, 2022–2029 (Usd Million)

Table 79 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Country, 2022–2029 (Usd Million)

Table 80 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Country, 2022–2029 (Usd Million)

Table 81 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Region, 2022–2029 (Usd Million)

Table 82 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Pegcetacoplan, By Country, 2022–2029 (Usd Million)

Table 83 Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Region, 2022–2029 (Usd Million)

Table 84 North America: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Country, 2022–2029 (Usd Million)

Table 85 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Country, 2022–2029 (Usd Million)

Table 86 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Country, 2022–2029 (Usd Million)

Table 87 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Country, 2022–2029 (Usd Million)

Table 88 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Region, 2022–2029 (Usd Million)

Table 89 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Other Molecules, By Country, 2022–2029 (Usd Million)

Table 90 Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 91 Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Region, 2022–2029 (Usd Million)

Table 92 North America: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Country, 2022–2029 (Usd Million)

Table 93 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Country, 2022–2029 (Usd Million)

Table 94 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Country, 2022–2029 (Usd Million)

Table 95 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Country, 2022–2029 (Usd Million)

Table 96 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Region, 2022–2029 (Usd Million)

Table 97 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Biologics, By Country, 2022–2029 (Usd Million)

Table 98 Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Region, 2022–2029 (Usd Million)

Table 99 North America: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Country, 2022–2029 (Usd Million)

Table 100 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Country, 2022–2029 (Usd Million)

Table 101 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Country, 2022–2029 (Usd Million)

Table 102 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Country, 2022–2029 (Usd Million)

Table 103 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Region, 2022–2029 (Usd Million)

Table 104 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Biosimilars, By Country, 2022–2029 (Usd Million)

Table 105 Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 106 Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Region, 2022–2029 (Usd Million)

Table 107 North America: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Country, 2022–2029 (Usd Million)

Table 108 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Country, 2022–2029 (Usd Million)

Table 109 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Country, 2022–2029 (Usd Million)

Table 110 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Country, 2022–2029 (Usd Million)

Table 111 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Region, 2022–2029 (Usd Million)

Table 112 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Wet Amd, By Country, 2022–2029 (Usd Million)

Table 113 Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Region, 2022–2029 (Usd Million)

Table 114 North America: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Country, 2022–2029 (Usd Million)

Table 115 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Country, 2022–2029 (Usd Million)

Table 116 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Country, 2022–2029 (Usd Million)

Table 117 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Country, 2022–2029 (Usd Million)

Table 118 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Region, 2022–2029 (Usd Million)

Table 119 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Dry Amd, By Country, 2022–2029 (Usd Million)

Table 120 Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 121 Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Region, 2022–2029 (Usd Million)

Table 122 North America: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Country, 2022–2029 (Usd Million)

Table 123 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Country, 2022–2029 (Usd Million)

Table 124 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Country, 2022–2029 (Usd Million)

Table 125 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Country, 2022–2029 (Usd Million)

Table 126 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Region, 2022–2029 (Usd Million)

Table 127 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Hospitals, By Country, 2022–2029 (Usd Million)

Table 128 Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Region, 2022–2029 (Usd Million)

Table 129 North America: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 130 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 131 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 132 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 133 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Region, 2022–2029 (Usd Million)

Table 134 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Long-term Care Facilities, By Country, 2022–2029 (Usd Million)

Table 135 Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Region, 2022–2029 (Usd Million)

Table 136 North America: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Country, 2022–2029 (Usd Million)

Table 137 Europe: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Country, 2022–2029 (Usd Million)

Table 138 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Country, 2022–2029 (Usd Million)

Table 139 Latin America: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Country, 2022–2029 (Usd Million)

Table 140 Middle East: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Region, 2022–2029 (Usd Million)

Table 141 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market For Specialty Centers, By Country, 2022–2029 (Usd Million)

Table 142 Age-related Macular Degeneration (Amd) Drugs Market, By Region, 2022–2029 (Usd Million)

Table 143 North America: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 144 North America: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 145 North America: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 146 North America: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 147 North America: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 148 North America: Age-related Macular Degeneration (Amd) Drugs Market, By Country, 2022–2029 (Usd Million)

Table 149 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In North America

Table 150 Us Healthcare Spending, 2020–2022 (Usd Million)

Table 151 Us: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 152 Us: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 153 Us: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 154 Us: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 155 Us: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 156 Canada: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 157 Canada: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 158 Canada: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 159 Canada: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 160 Canada: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 161 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 162 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 163 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 164 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 165 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 166 Europe: Age-related Macular Degeneration (Amd) Drugs Market,

By Country, 2022–2029 (Usd Million)

Table 167 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In Europe

Table 168 Germany: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 169 Germany: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 170 Germany: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 171 Germany: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 172 Germany: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 173 Uk: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 174 Uk: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 175 Uk: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 176 Uk: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 177 Uk: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 178 France: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 179 France: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 180 France: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 181 France: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 182 France: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 183 Italy: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 184 Italy: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 185 Italy: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 186 Italy: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 187 Italy: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 188 Spain: Age-related Macular Degeneration (Amd) Market, By Product, 2022–2029 (Usd Million)

Table 189 Spain: Age-related Macular Degeneration (Amd) Market, By Molecule, 2022–2029 (Usd Million)

Table 190 Spain: Age-related Macular Degeneration (Amd) Market, By Approval Type, 2022–2029 (Usd Million)

Table 191 Spain: Age-related Macular Degeneration (Amd) Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 192 Spain: Age-related Macular Degeneration (Amd) Market, By End User, 2022–2029 (Usd Million)

Table 193 Netherlands: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 194 Netherlands: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 195 Netherlands: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 196 Netherlands: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 197 Netherlands: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 198 Rest Of Europe: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 199 Rest Of Europe: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 200 Rest Of Europe: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 201 Rest Of Europe: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 202 Rest Of Europe: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 203 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 204 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 205 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 206 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 207 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 208 Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market,

By Country, 2022–2029 (Usd Million)

Table 209 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In Asia Pacific

Table 210 China: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 211 China: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 212 China: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 213 China: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 214 China: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 215 Japan: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 216 Japan: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 217 Japan: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 218 Japan: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 219 Japan: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 220 India: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 221 India: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 222 India: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 223 India: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 224 India: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 225 Australia: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 226 Australia: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 227 Australia: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 228 Australia: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 229 Australia: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 230 South Korea: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 231 South Korea: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 232 South Korea: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 233 South Korea: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 234 South Korea: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 235 Rest Of Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 236 Rest Of Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 237 Rest Of Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 238 Rest Of Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 239 Rest Of Asia Pacific: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 240 Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 241 Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 242 Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 243 Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 244 Latin America: Age-related Macular Degeneration (Amd) Market,

By End User, 2022–2029 (Usd Million)

Table 245 Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Country, 2022–2029 (Usd Million)

Table 246 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In Latin America

Table 247 Brazil: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 248 Brazil: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 249 Brazil: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 250 Brazil: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 251 Brazil: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 252 Mexico: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 253 Mexico: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 254 Mexico: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 255 Mexico: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 256 Mexico: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 257 Rest Of Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 258 Rest Of Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 259 Rest Of Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 26 0 Rest Of Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 261 Rest Of Latin America: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 262 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 263 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 264 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 265 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 266 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 267 Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Region, 2022–2029 (Usd Million)

Table 268 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In Middle East

Table 269 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 270 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 271 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 272 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 273 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 274 Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Country, 2022–2029 (Usd Million)

Table 275 Saudi Arabia: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 276 Saudi Arabia: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 277 Saudi Arabia: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 278 Saudi Arabia: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 279 Saudi Arabia: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 280 Uae: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 281 Uae: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 282 Uae: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 283 Uae: Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2022–2029 (Usd Million)

Table 284 Uae: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 285 Other Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 286 Other Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 287 Other Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 288 Other Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 289 Other Gcc Countries: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 290 Rest Of Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2022–2029 (Usd Million)

Table 291 Rest Of Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2022–2029 (Usd Million)

Table 292 Rest Of Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Approval Type, 2022–2029 (Usd Million)

Table 293 Rest Of Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 294 Rest Of Middle East: Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2022–2029 (Usd Million)

Table 295 Africa: Age-related Macular Degeneration (Amd) Drugs Market,

By Product, 2022–2029 (Usd Million)

Table 296 Africa: Age-related Macular Degeneration (Amd) Drugs Market,

By Molecule, 2022–2029 (Usd Million)

Table 297 Africa: Age-related Macular Degeneration (Amd) Drugs Market,

By Approval Type, 2022–2029 (Usd Million)

Table 298 Africa: Age-related Macular Degeneration (Amd) Drugs Market, By Type Of Amd, 2022–2029 (Usd Million)

Table 299 Africa: Age-related Macular Degeneration (Amd) Drugs Market,

By End User, 2022–2029 (Usd Million)

Table 300 Macroeconomic Outlook For Age-related Macular Degeneration (Amd) Drugs Market In Africa

Table 301 Overview Of Strategies Deployed By Key Players In Age-related Macular Degeneration (Amd) Drugs Market

Table 302 Age-related Macular Degeneration (Amd) Drugs Market:

Degree Of Competition

Table 303 Age-related Macular Degeneration (Amd) Drugs Market:

Molecule Footprint

Table 304 Age-related Macular Degeneration (Amd) Drugs Market:

Approval Type Footprint

Table 305 Age-related Macular Degeneration (Amd) Drugs Market:

Type Of Amd Footprint

Table 306 Age-related Macular Degeneration (Amd) Drugs Market:

Region Footprint

Table 307 Age-related Macular Degeneration (Amd) Drugs Market:

Detailed List Of Key Startups/Smes

Table 308 Age-related Macular Degeneration (Amd) Drugs Market:

Competitive Benchmarking Of Key Startups/Smes

Table 309 Age-related Macular Degeneration (Amd) Drugs Market:

Product Launches & Approvals, January 2021–august 2024

Table 310 Age-related Macular Degeneration (Amd) Drugs Market:

Deals, January 2021– August 2024

Table 311 Age-related Macular Degeneration (Amd) Drugs Market: Expansions, January 2021–august 2024

Table 312 F. Hoffmann-la Roche Ltd: Company Overview

Table 313 F. Hoffmann-la Roche Ltd: Products Offered

Table 314 F. Hoffmann-la Roche Ltd: Product Launches & Approvals,

January 2021–august 2024

Table 315 Regeneron Pharmaceuticals Inc.: Company Overview

Table 316 Regeneron Pharmaceuticals Inc.: Products Offered

Table 317 Regeneron Pharmaceuticals Inc.: Product Launches & Approvals, January 2021–august 2024

Table 318 Novartis Ag: Company Overview

Table 319 Novartis Ag: Products Offered

Table 320 Novartis Ag: Product Launches & Approvals, January 2021–august 2024

Table 321 Novartis Ag: Deals, January 2021–august 2024

Table 322 Bayer Ag: Company Overview

Table 323 Bayer Ag: Products Offered

Table 324 Bayer Ag: Product Launches & Approvals, January 2021–august 2024

Table 325 Apellis Pharmaceuticals: Company Overview

Table 326 Apellis Pharmaceuticals: Products Offered

Table 327 Apellis Pharmaceuticals: Product Launches & Approvals,

January 2021–august 2024

Table 328 Apellis Pharmaceuticals: Deals, January 2021–august 2024

Table 329 Astellas Pharma Inc.: Company Overview

Table 330 Astellas Pharma Inc.: Products Offered

Table 331 Astellas Pharma Inc.: Product Launches & Approvals,

January 2021–august 2024

Table 332 Astellas Pharma Inc.: Deals, January 2021–august 2024

Table 333 Stada Arzneimittel Ag: Company Overview

Table 334 Stada Arzneimittel Ag: Products Offered

Table 335 Stada Arzneimittel Ag: Product Launches & Approvals,

January 2021–august 2024

Table 336 Stada Arzneimittel Ag: Deals, January 2021–august 2024

Table 337 Biogen: Company Overview

Table 338 Biogen: Products Offered

Table 339 Biogen: Product Launches & Approvals, January 2021–august 2024

Table 340 Formycon Ag: Company Overview

Table 341 Formycon Ag: Products Offered

Table 342 Formycon Ag: Product Launches & Approvals,

January 2021–august 2024

Table 343 Formycon Ag: Deals, January 2021–august 2024

Table 344 Coherus Biosciences: Company Overview

Table 345 Coherus Biosciences: Products Offered

Table 346 Coherus Biosciences: Product Launches & Approvals,

January 2021–august 2024

Table 347 Coherus Biosciences: Other Developments, January 2021–august 2024

Table 348 Biocon: Company Overview

Table 349 Biocon: Products Offered

Table 350 Biocon: Product Launches & Approvals, January 2021–august 2024

Table 351 Biocon: Deals, January 2021–august 2024

Table 352 Outlook Therapeutics, Inc.: Company Overview

Table 353 Outlook Therapeutics, Inc.: Products Offered

Table 354 Outlook Therapeutics, Inc.: Product Launches & Approvals,

January 2021–august 2024

Table 355 Outlook Therapeutics, Inc.: Deals, January 2021–august 2024

Table 356 Teva Pharmaceutical Industries Ltd.: Company Overview

Table 357 Teva Pharmaceutical Industries Ltd.: Products Offered

Table 358 Teva Pharmaceutical Industries Ltd.: Product Launches & Approvals, January 2021–august 2024

Table 359 Teva Pharmaceutical Industries Ltd.: Deals, January 2021–august 2024

Table 360 Intas Pharmaceuticals Ltd.: Company Overview

Table 361 Intas Pharmaceuticals Ltd.: Products Offered

Table 362 Sandoz Group Ag: Company Overview

Table 363 Sandoz Group Ag: Products Offered

Table 364 Sandoz Group Ag: Product Launches & Approvals,

January 2021–august 2024

Table 365 Sandoz Group Ag: Deals, January 2021–august 2024

Table 366 Sandoz Group Ag: Expansions, January 2021–august 2024

Table 367 Chengdu Kanghong Pharmaceutical Group Co., Ltd.: Company Overview

Table 368 Chengdu Kanghong Pharmaceutical Group Co., Ltd.: Products Offered

Table 369 Ocular Therapeutix, Inc.: Company Overview

Table 370 Opthea Limited: Company Overview

Table 371 Kodiak Sciences Inc.: Company Overview

Table 372 Bio-thera: Company Overview

Table 373 Amgen Inc.: Company Overview

Table 374 Alvotech: Company Overview

Table 375 Stealth Biotherapeutics Inc.: Company Overview

Table 376 Alteogen Inc.: Company Overview

Table 377 Ocumension Therapeutics: Company Overview

Table 378 Innovent: Company Overview

Table 379 Shanghai Henlius Biotech, Inc.: Company Overview

Figures List

Figure 1 Age-related Macular Degeneration (Amd) Drugs Market Segmentation

Figure 2 Research Design

Figure 3 Age-related Macular Degeneration (Amd) Drugs Market:

Breakdown Of Primary Interviews

Figure 4 Market Size Estimation: Supply-side Analysis, 2023

Figure 5 Age-related Macular Degeneration (Amd) Drugs Market:

Revenue Share Analysis, 2023

Figure 6 Illustrative Example Of F. Hoffmann-la Roche Ltd: Company Revenue Share Analysis, 2023

Figure 7 Market Validation From Primary Experts

Figure 8 Bottom-up Approach

Figure 9 Age-related Macular Degeneration (Amd) Drugs Market:

Cagr Projections, 2024–2029

Figure 10 Age-related Macular Degeneration (Amd) Drugs Market:

Growth Analysis Of Market Dynamics

Figure 11 Data Triangulation

Figure 12 Age-related Macular Degeneration (Amd) Drugs Market, By Product, 2024 Vs. 2029 (Usd Million)

Figure 13 Age-related Macular Degeneration (Amd) Drugs Market, By Molecule, 2024 Vs. 2029 (Usd Million)

Figure 14 Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Amd, 2024 Vs. 2029 (Usd Million)

Figure 15 Age-related Macular Degeneration (Amd) Drugs Market,

By Type Of Approval, 2024 Vs. 2029 (Usd Million)

Figure 16 Age-related Macular Degeneration (Amd) Drugs Market, By End User, 2024 Vs. 2029 (Usd Million)

Figure 17 Age-related Macular Degeneration (Amd) Drugs Market,

By Region, 2024–2029

Figure 18 Growing Geriatric Population And Changing Lifestyles To Drive Market

Figure 19 Biologics Segment And Us Dominated North American Market In 2023

Figure 20 Wet Amd Segment To Lead Market By 2029

Figure 21 Hospitals Segment Accounted For Largest Market Share In 2023

Figure 22 North America To Register Highest Cagr During Forecast Period

Figure 23 Age-related Macular Degeneration (Amd) Drugs Market:

Drivers, Restraints, Opportunities, And Challenges

Figure 24 Revenue Shift & New Pockets For Age-related Macular

Degeneration Therapy Providers

Figure 25 Average Selling Price Of Age-related Macular Degeneration (Amd) Drugs, By Region, 2021–2023 (Usd)

Figure 26 Age-related Macular Degeneration (Amd) Drugs Market:

Value Chain Analysis

Figure 27 Age-related Macular Degeneration (Amd) Drugs Market:

Supply Chain Analysis

Figure 28 Age-related Macular Degeneration (Amd) Drugs Market:

Ecosystem Analysis

Figure 29 Age-related Macular Degeneration (Amd) Drugs Market:

Patent Analysis, 2014–2024

Figure 30 Age-related Macular Degeneration (Amd) Drugs Market:

Porter’s Five Forces Analysis

Figure 31 Influence Of Stakeholders On Buying Process Of Age-related

Macular Degeneration (Amd) Drugs

Figure 32 Key Buying Criteria, By End User

Figure 33 Impact Of Artificial Intelligence On Age-related Macular

Degeneration (Amd) Drugs Market

Figure 34 North America: Age-related Macular Degeneration (Amd)

Drugs Market Snapshot

Figure 35 Asia Pacific: Age-related Macular Degeneration (Amd)

Drugs Market Snapshot

Figure 36 Revenue Analysis Of Key Players, 2021–2023 (Usd Million)

Figure 37 Market Share Analysis Of Key Players, 2023

Figure 38 Age-related Macular Degeneration (Amd) Drugs Market: Company Evaluation Matrix (Key Players), 2023

Figure 39 Age-related Macular Degeneration (Amd) Drugs Market:

Company Footprint

Figure 40 Age-related Macular Degeneration (Amd) Drugs Market:

Company Evaluation Matrix (Startups/Smes), 2023

Figure 41 Year-to-date (Ytd) Price Total Return And 5-year Stock

Beta Of Key Vendors

Figure 42 Ev/Ebitda Of Key Vendors

Figure 43 Age-related Macular Degeneration (Amd) Drugs Market: Brand/Product Comparison

Figure 44 F. Hoffmann-la Roche Ltd: Company Snapshot (2023)

Figure 45 Regeneron Pharmaceuticals Inc.: Company Snapshot (2023)

Figure 46 Novartis Ag: Company Snapshot (2023)

Figure 47 Bayer Ag: Company Snapshot (2023)

Figure 48 Astellas Pharma Inc.: Company Snapshot (2023)

Figure 49 Stada Arzneimittel Ag: Company Snapshot (2023)

Figure 50 Biogen: Company Snapshot (2023)

Figure 51 Formycon Ag: Company Snapshot (2023)

Figure 52 Biocon: Company Snapshot (2023)

Figure 53 Teva Pharmaceutical Industries Ltd.: Company Snapshot (2023)

Figure 54 Sandoz Group Ag: Company Snapshot (2023)